Exelixis, Inc.
EXEL
Rang in aandelen
#1366
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Aandeelprijs
$64.31
Marktkapitalisatie
$16.16B
Verandering (1 dag)
-0.13%
Verandering (1 jaar)
77.98%
Land
US
Handel Exelixis, Inc. (EXEL)
Categorie
Healthcare
Omzet van Exelixis, Inc. (EXEL)
Omzet in Jul 2026 TTM: $2.44B
Volgens de laatste financiële rapporten van Exelixis, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $2.44B. In 2025 behaalde het bedrijf een omzet van $2.17B een stijging ten opzichte van de omzet in het jaar 2023, die $1.83B bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Exelixis, Inc. van 2000 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $2.44B | 12.32% |
| 2025 | $2.17B | 18.49% |
| 2023 | $1.83B | 13.60% |
| 2022 | $1.61B | 12.27% |
| 2021 | $1.43B | 45.31% |
| 2020 | $987.54M | 2.04% |
| 2019 | $967.78M | 13.35% |
| 2018 | $853.83M | 88.70% |
| 2017 | $452.48M | 136.34% |
| 2016 | $191.45M | 415.05% |
| 2015 | $37.17M | 48.03% |
| 2014 | $25.11M | -19.87% |
| 2013 | $31.34M | -33.96% |
| 2012 | $47.45M | -83.62% |
| 2011 | $289.64M | 56.52% |
| 2010 | $185.05M | 21.93% |
| 2009 | $151.76M | 28.76% |
| 2008 | $117.86M | 3.87% |
| 2007 | $113.47M | 15.00% |
| 2006 | $98.67M | 29.90% |
| 2005 | $75.96M | 43.71% |
| 2004 | $52.86M | 2.56% |
| 2003 | $51.54M | 16.29% |
| 2002 | $44.32M | 8.09% |
| 2001 | $41.01M | 65.62% |
| 2000 | $24.76M | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 418.26% |
US
|
|
| $2.23B | -8.54% |
US
|
|
| $15.74B | 546.34% |
AU
|
|
| $6.02B | 147.19% |
NL
|
|
| - | - |
CH
|
